IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지
DOI QR코드

DOI QR Code

Exploring the Potential of Glycolytic Modulation in Myeloid-Derived Suppressor Cells for Immunotherapy and Disease Management

  • Jisu Kim (College of Pharmacy, Chung-Ang University) ;
  • Jee Yeon Choi (College of Pharmacy, Chung-Ang University) ;
  • Hyeyoung Min (College of Pharmacy, Chung-Ang University) ;
  • Kwang Woo Hwang (College of Pharmacy, Chung-Ang University)
  • Received : 2024.01.03
  • Accepted : 2024.04.29
  • Published : 2024.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Recent advancements in various technologies have shed light on the critical role of metabolism in immune cells, paving the way for innovative disease treatment strategies through immunometabolism modulation. This review emphasizes the glucose metabolism of myeloid-derived suppressor cells (MDSCs), an emerging pivotal immunosuppressive factor especially within the tumor microenvironment. MDSCs, an immature and heterogeneous myeloid cell population, act as a double-edged sword by exacerbating tumors or mitigating inflammatory diseases through their immune-suppressive functions. Numerous recent studies have centered on glycolysis of MDSC, investigating the regulation of altered glycolytic pathways to manage diseases. However, the specific changes in MDSC glycolysis and their exact functions continue to be areas of ongoing discussion yet. In this paper, we review a range of current findings, including the latest research on the alteration of glycolysis in MDSCs, the consequential functional alterations in these cells, and the outcomes of attempts to modulate MDSC functions by regulating glycolysis. Ultimately, we will provide insights into whether these research efforts could be translated into clinical applications.

Keywords

Acknowledgement

This work was supported by grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT 2018R1A1A3A04078187 and 2021R1F1A1061287 (to H. Min) and by the Ministry of Education 2021R1A6A3A01088432 (to J. Kim).

References

  1. Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: Not only in tumor immunity. Front Immunol 2019;10:1099.
  2. Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer 2021;9:e003237.
  3. Colligan SH, Amitrano AM, Zollo RA, Peresie J, Kramer ED, Morreale B, Barbi J, Singh PK, Yu H, Wang J, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest 2022;132:e158661.
  4. Sun SH, Benner B, Savardekar H, Lapurga G, Good L, Abood D, Nagle E, Duggan M, Stiff A, DiVincenzo MJ, et al. Effect of immune checkpoint blockade on myeloid-derived suppressor cell populations in patients with melanoma. Front Immunol 2021;12:740890.
  5. Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JS, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, et al. Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin Cancer Res 2023;29:1209-1219.
  6. Owen DH, Benner B, Pilcher C, Good L, Savardekar H, Norman R, Ghattas C, Shah M, Konda B, Verschraegen CF, et al. Deep and durable response to nivolumab and temozolomide in small-cell lung cancer associated with an early decrease in myeloid-derived suppressor cells. Clin Lung Cancer 2021;22:e487-e497.
  7. Xiong X, Zhang Y, Wen Y. Diverse functions of myeloid-derived suppressor cells in autoimmune diseases. Immunol Res 2024;72:34-49.
  8. Park MJ, Lee SH, Kim EK, Lee EJ, Park SH, Kwok SK, Cho ML. Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus. Arthritis Rheumatol 2016;68:2717-2727.
  9. Wang Z, Zhu F, Wang J, Tao Q, Xu X, Wang H, Xiong S, Wang Y, Zhai Z. Increased CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells correlate with disease severity in systemic lupus erythematosus patients in an iNOS-dependent manner. Front Immunol 2019;10:1202.
  10. Wu H, Zhen Y, Ma Z, Li H, Yu J, Xu ZG, Wang XY, Yi H, Yang YG. Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus. Sci Transl Med 2016;8:331ra40.
  11. Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, Shen Y, Esserman DA, Little P, Schwartz TA, et al. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol 2015;97:573-582.
  12. Zhang H, Wang S, Huang Y, Wang H, Zhao J, Gaskin F, Yang N, Fu SM. Myeloid-derived suppressor cells are proinflammatory and regulate collagen-induced arthritis through manipulating Th17 cell differentiation. Clin Immunol 2015;157:175-186.
  13. Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe KI. Dextran sulphate sodium increases splenic Gr1(+) CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin Exp Immunol 2011;164:417-427.
  14. Kontaki E, Boumpas DT, Tzardi M, Mouzas IA, Papadakis KA, Verginis P. Aberrant function of myeloid-derived suppressor cells (MDSCs) in experimental colitis and in inflammatory bowel disease (IBD) immune responses. Autoimmunity 2017;50:170-181.
  15. Wang Y, Liu H, Zhang Z, Bian D, Shao K, Wang S, Ding Y. G-MDSC-derived exosomes mediate the differentiation of M-MDSC into M2 macrophages promoting colitis-to-cancer transition. J Immunother Cancer 2023;11:e006166.
  16. Oren R, Farnham AE, Saito K, Milofsky E, Karnovsky ML. Metabolic patterns in three types of phagocytizing cells. J Cell Biol 1963;17:487-501.
  17. Purohit V, Wagner A, Yosef N, Kuchroo VK. Systems-based approaches to study immunometabolism. Cell Mol Immunol 2022;19:409-420.
  18. Baker SA, Rutter J. Metabolites as signalling molecules. Nat Rev Mol Cell Biol 2023;24:355-374.
  19. Xu Y, Chen Y, Zhang X, Ma J, Liu Y, Cui L, Wang F. Glycolysis in innate immune cells contributes to autoimmunity. Front Immunol 2022;13:920029.
  20. Martins CP, New LA, O'Connor EC, Previte DM, Cargill KR, Tse IL, Sims-Lucas S, Piganelli JD. Glycolysis inhibition induces functional and metabolic exhaustion of cd4(+) t cells in type 1 diabetes. Front Immunol 2021;12:669456.
  21. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425.
  22. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-689.
  23. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000;165:779-785.
  24. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010;185:2273-2284.
  25. Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 2015;98:913-922.
  26. Karin N. The development and homing of myeloid-derived suppressor cells: From a two-stage model to a multistep narrative. Front Immunol 2020;11:557586.
  27. Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory t cells within the immunosuppressive tumor microenvironment. Cancers (Basel) 2021;13:210.
  28. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016;7:12150.
  29. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 2021;6:362.
  30. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. eLife 2016;5:e17375.
  31. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 2021;21:485-498.
  32. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013;14:211-220.
  33. Geltink RI, Kyle RL, Pearce EL. Unraveling the complex interplay between t cell metabolism and function. Annu Rev Immunol 2018;36:461-488.
  34. Fu C, Fu Z, Jiang C, Xia C, Zhang Y, Gu X, Zheng K, Zhou D, Tang S, Lyu S, et al. CD205+ polymorphonuclear myeloid-derived suppressor cells suppress antitumor immunity by overexpressing GLUT3. Cancer Sci 2021;112:1011-1025.
  35. Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011;118:5498-5505.
  36. Aintablian A, Strozniak S, Heuer M, Lutz MB. M-MDSC in vitro generation from mouse bone marrow with IL-3 reveals high expression and functional activity of arginase 1. Front Immunol 2023;14:1130600.
  37. Li F, Zhao Y, Wei L, Li S, Liu J. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther 2018;19:695-705.
  38. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 2010;70:68-77.
  39. Roy DG, Kaymak I, Williams KS, Ma EH, Jones RG. Immunometabolism in the tumor microenvironment. Annual Review of Cancer Biology 2021;5:137-159.
  40. Tukiman MH, Norazmi MN. Immunometabolism of immune cells in mucosal environment drives effector responses against mycobacterium tuberculosis. Int J Mol Sci 2022;23:8531.
  41. Sun JX, Xu XH, Jin L. Effects of metabolism on macrophage polarization under different disease backgrounds. Front Immunol 2022;13:880286.
  42. Peng Y, Zhou M, Yang H, Qu R, Qiu Y, Hao J, Bi H, Guo D. Regulatory mechanism of M1/M2 macrophage polarization in the development of autoimmune diseases. Mediators Inflamm 2023;2023:8821610.
  43. Kieler M, Hofmann M, Schabbauer G. More than just protein building blocks: how amino acids and related metabolic pathways fuel macrophage polarization. FEBS J 2021;288:3694-3714.
  44. Hammami I, Chen J, Murschel F, Bronte V, De Crescenzo G, Jolicoeur M. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol 2012;13:18.
  45. Jian SL, Chen WW, Su YC, Su YW, Chuang TH, Hsu SC, Huang LR. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis 2017;8:e2779.
  46. Kim J, Lee H, Choi HK, Min H. Discovery of myeloid-derived suppressor cell-specific metabolism by metabolomic and lipidomic profiling. Metabolites 2023;13:13.
  47. Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M. Prevention of tumor growth and dissemination by in situ vaccination with mitochondria-targeted atovaquone. Adv Sci (Weinh) 2022;9:e2101267.
  48. Dietrich O, Heinz A, Goldmann O, Geffers R, Beineke A, Hiller K, Saliba AE, Medina E. Dysregulated immunometabolism is associated with the generation of myeloid-derived suppressor cells in staphylococcus aureus chronic infection. J Innate Immun 2022;14:257-274.
  49. Wu T, Zhao Y, Wang H, Li Y, Shao L, Wang R, Lu J, Yang Z, Wang J, Zhao Y. mTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors. Sci Rep 2016;6:20250.
  50. Deng Y, Yang J, Luo F, Qian J, Liu R, Zhang D, Yu H, Chu Y. mTOR-mediated glycolysis contributes to the enhanced suppressive function of murine tumor-infiltrating monocytic myeloid-derived suppressor cells. Cancer Immunol Immunother 2018;67:1355-1364.
  51. Goldmann O, Medina E. Myeloid-derived suppressor cells impair CD4+ T cell responses during chronic Staphylococcus aureus infection via lactate metabolism. Cell Mol Life Sci 2023;80:221.
  52. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J Immunol 2013;191:1486-1495.
  53. Wang S, Tan Q, Hou Y, Dou H. Emerging roles of myeloid-derived suppressor cells in diabetes. Front Pharmacol 2021;12:798320.
  54. Zou Z, Tao T, Li H, Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 2020;10:31.
  55. Taylor CT, Scholz CC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol 2022;18:573-587.
  56. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013;17:113-124.
  57. Zhang C, Wang S, Li J, Zhang W, Zheng L, Yang C, Zhu T, Rong R. The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Cell Death Dis 2017;8:e2695.
  58. Li X, Li Y, Yu Q, Xu L, Fu S, Wei C, Wang L, Luo Y, Shi J, Qian P, et al. mTOR signaling regulates the development and therapeutic efficacy of PMN-MDSCs in acute GVHD. Front Cell Dev Biol 2021;9:741911.
  59. Li Y, Xu Y, Liu X, Yan X, Lin Y, Tan Q, Hou Y. mTOR inhibitor INK128 promotes wound healing by regulating MDSCs. Stem Cell Res Ther 2021;12:170.
  60. Kotze LA, Leukes VN, Fang Z, Lutz MB, Fitzgerald BL, Belisle J, Loxton AG, Walzl G, du Plessis N. Evaluation of autophagy mediators in myeloid-derived suppressor cells during human tuberculosis. Cell Immunol 2021;369:104426.
  61. Shi G, Li D, Zhang D, Xu Y, Pan Y, Lu L, Li J, Xia X, Dou H, Hou Y. IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development. Cell Death Dis 2021;7:179.
  62. Nakamura T, Nakao T, Yoshimura N, Ashihara E. Rapamycin prolongs cardiac allograft survival in a mouse model by inducing myeloid-derived suppressor cells. Am J Transplant 2015;15:2364-2377.
  63. Kostlin-Gille N, Dietz S, Schwarz J, Spring B, Pauluschke-Frohlich J, Poets CF, Gille C. HIF-1alpha-deficiency in myeloid cells leads to a disturbed accumulation of myeloid derived suppressor cells (MDSC) during pregnancy and to an increased abortion rate in mice. Front Immunol 2019;10:161.
  64. Li J, Wang L, Chen X, Li L, Li Y, Ping Y, Huang L, Yue D, Zhang Z, Wang F, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. OncoImmunology 2017;6:e1320011.
  65. Travelli C, Consonni FM, Sangaletti S, Storto M, Morlacchi S, Grolla AA, Galli U, Tron GC, Portararo P, Rimassa L, et al. Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. Cancer Res 2019;79:1938-1951.
  66. Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, Liu J, Lai S, Luo D, Wang L, et al. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res 2020;8:1440-1451.
  67. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007;21:1037-1049.
  68. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211:781-790.
  69. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207:2439-2453.
  70. Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido A, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, et al. AMPK alpha-1 intrinsically regulates the function and differentiation of tumor myeloid-derived suppressor cells. Cancer Res 2019;79:5034-5047.
  71. Rong Y, Yuan CH, Qu Z, Zhou H, Guan Q, Yang N, Leng XH, Bu L, Wu K, Wang FB. Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2. Sci Rep 2016;6:23824.
  72. Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, et al. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. OncoImmunology 2016;5:e1214787.
  73. Kim SH, Li M, Trousil S, Zhang Y, Pasca di Magliano M, Swanson KD, Zheng B. Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma. J Invest Dermatol 2017;137:1740-1748.
  74. Uehara T, Eikawa S, Nishida M, Kunisada Y, Yoshida A, Fujiwara T, Kunisada T, Ozaki T, Udono H. Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol 2019;31:187-198.
  75. Kang J, Lee D, Lee KJ, Yoon JE, Kwon JH, Seo Y, Kim J, Chang SY, Park J, Kang EA, et al. Tumor-suppressive effect of metformin via the regulation of m2 macrophages and myeloid-derived suppressor cells in the tumor microenvironment of colorectal cancer. Cancers (Basel) 2022;14:2881.
  76. Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res 2018;78:1779-1791.
  77. Salminen A, Kauppinen A, Kaarniranta K. AMPK activation inhibits the functions of myeloid-derived suppressor cells (MDSC): impact on cancer and aging. J Mol Med (Berl) 2019;97:1049-1064.
  78. Boyer T, Blaye C, Larmonier N, Domblides C. Influence of the metabolism on myeloid cell functions in cancers: clinical perspectives. Cells 2022;11:11.
  79. Kornberg MD. The immunologic Warburg effect: evidence and therapeutic opportunities in autoimmunity. Wiley Interdiscip Rev Syst Biol Med 2020;12:e1486.
  80. Seth P, Csizmadia E, Hedblom A, Vuerich M, Xie H, Li M, Longhi MS, Wegiel B. Deletion of lactate dehydrogenase-a in myeloid cells triggers antitumor immunity. Cancer Res 2017;77:3632-3643.
  81. Mohammadpour H, MacDonald CR, McCarthy PL, Abrams SI, Repasky EA. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Reports 2021;37:109883.
  82. Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, Laketa V, Donakonda S, Ahting U, Lorenz-Depiereux B, et al. Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal. Nat Immunol 2020;21:555-566.
  83. Allaman I, Belanger M, Magistretti PJ. Methylglyoxal, the dark side of glycolysis. Front Neurosci 2015;9:23.
  84. Qi J, Zhou X, Bai Z, Lu Z, Zhu X, Liu J, Wang J, Jin M, Liu C, Li X. FcγRIIIA activation-mediated upregulation of glycolysis alters MDSCs modulation in CD4+ T cell subsets of Sjogren syndrome. Cell Death Dis 2023;14:86.
  85. Chen X, Zhang Z, Bi Y, Fu Z, Gong P, Li Y, Yu Q, Jia A, Wang J, Xue L, et al. mTOR signaling disruption from myeloid-derived suppressive cells protects against immune-mediated hepatic injury through the HIF1α-dependent glycolytic pathway. J Leukoc Biol 2016;100:1349-1362.
  86. Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TD, Ugel S, et al. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Sci Immunol 2019;4:eaax8189.
  87. Tohumeken S, Baur R, Bottcher M, Stoll A, Loschinski R, Panagiotidis K, Braun M, Saul D, Volkl S, Baur AS, et al. Palmitoylated proteins on AML-derived extracellular vesicles promote myeloid-derived suppressor cell differentiation via TLR2/Akt/mTOR signaling. Cancer Res 2020;80:3663-3676.
  88. Zhang Z, Zheng Y, Chen Y, Yin Y, Chen Y, Chen Q, Hou Y, Shen S, Lv M, Wang T. Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis. Exp Hematol Oncol 2022;11:88.
  89. Roy S, Dukic T, Bhandary B, Tu KJ, Molitoris J, Ko YH, Shukla HD. 3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model. Am J Cancer Res 2022;12:4977-4987.
  90. Consiglio CR, Udartseva O, Ramsey KD, Bush C, Gollnick SO. Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression. Cancer Immunol Res 2020;8:1215-1227.
  91. Meng G, Li B, Chen A, Zheng M, Xu T, Zhang H, Dong J, Wu J, Yu D, Wei J. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma. Br J Cancer 2020;122:111-120.
  92. Shi ZY, Yang C, Lu LY, Lin CX, Liang S, Li G, Zhou HM, Zheng JM. Inhibition of hexokinase 2 with 3-BrPA promotes MDSCs differentiation and immunosuppressive function. Cell Immunol 2023;385:104688.
  93. Yan J, Li A, Chen X, Cao K, Song M, Guo S, Li Z, Huang S, Li Z, Xu D, et al. Glycolysis inhibition ameliorates brain injury after ischemic stroke by promoting the function of myeloid-derived suppressor cells. Pharmacol Res 2022;179:106208.
  94. Jia A, Wang Y, Wang Y, Li Y, Yang Q, Cao Y, He Y, Dong L, Dong Y, Hou Y, et al. The kinase AKT1 potentiates the suppressive functions of myeloid-derived suppressor cells in inflammation and cancer. Cell Mol Immunol 2021;18:1074-1076.
  95. Liu G, Bi Y, Shen B, Yang H, Zhang Y, Wang X, Liu H, Lu Y, Liao J, Chen X, et al. SIRT1 limits the function and fate of myeloid-derived suppressor cells in tumors by orchestrating HIF-1α-dependent glycolysis. Cancer Res 2014;74:727-737.
  96. Hammami A, Abidin BM, Charpentier T, Fabie A, Duguay AP, Heinonen KM, Stager S. HIF-1α is a key regulator in potentiating suppressor activity and limiting the microbicidal capacity of MDSC-like cells during visceral leishmaniasis. PLoS Pathog 2017;13:e1006616.
  97. Lu Y, Liu H, Bi Y, Yang H, Li Y, Wang J, Zhang Z, Wang Y, Li C, Jia A, et al. Glucocorticoid receptor promotes the function of myeloid-derived suppressor cells by suppressing HIF1α-dependent glycolysis. Cell Mol Immunol 2018;15:618-629.
  98. Dong P, Chen L, Wu H, Huo J, Jiang Z, Shao Y, Ren X, Huang J, Li X, Wang M, et al. Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia. Haematologica 2022;107:2834-2845.
  99. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009;8:3984-4001.
  100. Xu Y, Afify SM, Du J, Liu B, Hassan G, Wang Q, Li H, Liu Y, Fu X, Zhu Z, et al. The efficacy of PI3Kγ and EGFR inhibitors on the suppression of the characteristics of cancer stem cells. Sci Rep 2022;12:347.